Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jul;82(3):178-183.

Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs

Lisa R Bartner  1 , Stephanie McGrath  1 , Sangeeta Rao  1 , Linda K Hyatt  1 , Luke A Wittenburg  1
Affiliations
Randomized Controlled Trial

Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs

Lisa R Bartner et al. Can J Vet Res. 2018 Jul.

Abstract
in English, French

The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.

Le but de la présente étude était de déterminer la pharmacocinétique du cannbidiol (CBD) chez des chiens en santé. Trente chiens de recherche en santé ont été assignés à recevoir une des trois formulations (de l’huile micro-encapsulé dans des billes par voie orale, de l’huile infusé de CBD par voie orale, ou une crème infusée de CBD par voie transdermique), à une dose de 75 mg ou 150 mg q12h pendant 6 semaines. Les concentrations plasmatiques de cannabidiol ont été mesurées pendant les 12 premières heures et répétées après 2, 4 et 6 semaines. Les expositions systémiques les plus élevées ont été observées avec la formulation d’huile infusé de CBD administrée par voie orale et la demi-vie après une dose de 75 mg et de 150 mg était de 199,7 ± 55,9 et 127,5 ± 32,2 min, respectivement. L’exposition est proportionnelle à la dose et l’huile infusée de CBD par voie orale fournie le profile pharmacocinétique le plus favorable.(Traduit par Docteur Serge Messier).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Single-dose cannabidiol (CBD) plasma concentration. The 12-hour, single-dose CBD plasma concentration (mean +/− standard deviation) at 2 different dosages (75 mg, top; 150 mg, bottom) for transdermal cream, microencapsulated oil beads, and CBD-infused oil.
Figure 2
Figure 2
Cannabidiol (CBD) concentration at 6 wk. Maximal CBD plasma concentrations (mean +/− standard deviation) after twice-daily dosing for 2, 4, or 6 wk using 3 formulations. The lower dose (75 mg q12h) is represented on the left and the higher dose (150 mg q12h) on the right.
See this image and copyright information in PMC

References

    1. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006;105:1–25. - PubMed
    1. Abel EL. Marihuana, The First Twelve Thousand Years. New York, New York: Plenum Press; 1980.
    1. Russo E, Guy GW. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66:234–246. - PubMed
    1. Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Test Anal. 2014;6:24–30. - PubMed
    1. Podell M. Highs and lows of medical marijuana in the treatment of epilepsy. Proc Am Coll Vet Intern Med Forum. 2015:331–333.

Publication types